{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:30Z","timestamp":1794047370509,"version":"4.8.0"},"reference-count":26,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"12","license":[{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Selinexor is a selective inhibitor of nuclear export with anti-cancer properties. We performed a phase I study to determine the safety and maximum tolerated dose of selinexor when combined with high-dose dexamethasone, ifosfamide, carboplatin and etoposide (DICE) in relapsed\/refractory T-cell lymphoma (TCL) and natural-killer\/T-cell lymphoma (NKTL). Patients with relapsed\/refractory TCL and NKTL were treated with standard dose ICE, dexamethasone 20 mg on days 3 to 7, and escalating doses of oral selinexor on days 3, 5 and 7 in a 3+3 design. Dose levels (DL) 1, 2 and 3 were 40, 60 and 80 mg, respectively. Eleven patients with a median age of 60 years were enrolled; six at DL1 and five at DL2. Patients had received a median of two (range, 1-4) prior lines of treatment and seven had primary refractory disease at entry into the study. Patients received a median of three cycles (range, 1-6) of selinexor-DICE. The most common grade 1 or 2 toxicities included nausea (64%), fatigue (55%), and anorexia (45%) and the most common grade 3 or 4 toxicities included thrombocytopenia (82%), anemia (82%), neutropenia (73%), and hyponatremia (73%). Two patients developed dose-limiting toxicities at DL2 and one at DL1. Five patients discontinued treatment for reasons other than disease progression or lack of response. Of the ten evaluable patients, the overall and complete response rates were 91% and 82%, respectively. The maximum tolerated dose of selinexor was 40 mg when combined with DICE. The combination showed promising complete response rates in patients with relapsed\/refractory TCL and NKTL but was poorly tolerated. (clinicaltrials. gov identifier: NCT03212937).<\/jats:p>","DOI":"10.3324\/haematol.2020.251454","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T03:44:01Z","timestamp":1604547841000},"page":"3170-3175","source":"Crossref","is-referenced-by-count":15,"title":["Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer\/T-cell lymphoma"],"prefix":"10.3324","volume":"106","author":[{"given":"Tiffany","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagavalli","family":"Somasundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maica JD.","family":"Yunon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu Q.","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean X","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Farid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon T.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"key":"32176","doi-asserted-by":"crossref","unstructured":"Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non- Hodgkin's Lymphoma Classification Project. Ann Oncol. 1998; 9(7):717-720.","DOI":"10.1023\/A:1008265532487"},{"key":"32177","doi-asserted-by":"crossref","unstructured":"Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008; 26(25):4124-4130.","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"32178","doi-asserted-by":"crossref","unstructured":"Mak V, Hamm J, Chhanabhai M. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare longterm survivors. J Clin Oncol. 2013; 31(16):1970-1976.","DOI":"10.1200\/JCO.2012.44.7524"},{"key":"32179","doi-asserted-by":"crossref","unstructured":"Hwang WY, Koh LP, Lim ST. Multicenter study of comparative outcomes of hematopoietic stem cell transplant for peripheral T cell lymphoma and natural killer\/T-cell lymphoma. Leuk Lymphoma. 2011; 52(7):1382-1386.","DOI":"10.3109\/10428194.2011.569038"},{"key":"32180","doi-asserted-by":"crossref","unstructured":"Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014; 27:62-73.","DOI":"10.1016\/j.semcancer.2014.03.001"},{"key":"32181","doi-asserted-by":"crossref","unstructured":"Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH, Sun YJ. Prognostic value of CRM1 in pancreas cancer. Clin Invest Med. 2009; 32(6):e315.","DOI":"10.25011\/cim.v32i6.10668"},{"key":"32182","doi-asserted-by":"crossref","unstructured":"Noske A, Weichert W, Niesporek S. Expression of the nuclear export protein chromosomal region maintenance\/exportin 1\/Xpo1 is a prognostic factor in human ovarian cancer. Cancer. 2008; 112(8):1733-1743.","DOI":"10.1002\/cncr.23354"},{"key":"32183","doi-asserted-by":"crossref","unstructured":"Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery. 2009; 65(1):153-159.","DOI":"10.1227\/01.NEU.0000348550.47441.4B"},{"key":"32184","doi-asserted-by":"crossref","unstructured":"van der Watt PJ, Maske CP, Hendricks DT. The karyopherin proteins, Crm1 and karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer. 2009; 124(8):1829-1840.","DOI":"10.1002\/ijc.24146"},{"key":"32185","doi-asserted-by":"crossref","unstructured":"Kojima K, Kornblau SM, Ruvolo V. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013; 121(20):4166-4174.","DOI":"10.1182\/blood-2012-08-447581"},{"key":"32186","doi-asserted-by":"crossref","unstructured":"Engel R, Valkov NI, Gump JL, Hazlehurst L, Dalton WS, Sullivan DM. The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells. Exp Cell Res. 2004; 295(2):421-431.","DOI":"10.1016\/j.yexcr.2004.01.012"},{"key":"32187","doi-asserted-by":"crossref","unstructured":"Etchin J, Sanda T, Mansour MR. KPT- 330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol. 2013; 161(1):117-127.","DOI":"10.1111\/bjh.12231"},{"key":"32188","doi-asserted-by":"crossref","unstructured":"Turner JG, Marchion DC, Dawson JL. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res. 2009; 69(17):6899-6905.","DOI":"10.1158\/0008-5472.CAN-09-0484"},{"key":"32189","doi-asserted-by":"crossref","unstructured":"Muqbil I, Aboukameel A, Elloul S. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone. Cancer Lett. 2016; 383(2):309-317.","DOI":"10.1016\/j.canlet.2016.09.016"},{"key":"32190","doi-asserted-by":"crossref","unstructured":"Kuruvilla J, Savona M, Baz R. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin's lymphoma. Blood. 2017; 129(24):3175-3183.","DOI":"10.1182\/blood-2016-11-750174"},{"key":"32191","doi-asserted-by":"crossref","unstructured":"Abdul Razak AR, Mau-Soerensen M, Gabrail NY. First-in-class, first-inhuman phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol. 2016; 34(34):4142-4150.","DOI":"10.1200\/JCO.2015.65.3949"},{"key":"32192","doi-asserted-by":"crossref","unstructured":"Juweid ME, Wiseman GA, Vose JM. Response assessment of aggressive non- Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine- 18-fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2005; 23(21):4652-4661.","DOI":"10.1200\/JCO.2005.01.891"},{"key":"32193","doi-asserted-by":"crossref","unstructured":"Kuruvilla J, Gutierrez M, Shah BD. Preliminary evidence of anti tumor activity of selinexor (KPT-330) in a phase I trial of a first-in-class oral selective inhibitor of nuclear export (SINE) in patients with relapsed\/refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Blood. 2013; 122(21):90.","DOI":"10.1182\/blood.V122.21.90.90"},{"key":"32194","doi-asserted-by":"crossref","unstructured":"Tan DSP, Pang MY, Yong WP. Phase I study of the safety and tolerability of the Exportin 1 (XPO1) inhibitor selinexor (SXR) in Asian patients (pts) with advanced solid cancers. J Clin Oncol. 2015; 22(15 suppl):2542.","DOI":"10.1200\/jco.2015.33.15_suppl.2542"},{"key":"32195","doi-asserted-by":"crossref","unstructured":"Sweet K, Komrokji R, Padron E. Phase I clinical trial of selinexor in combination with daunorubicin and cytarabine in previously untreated poor-risk acute myeloid leukemia. Clin Cancer Res. 2020; 26(1):54-60.","DOI":"10.1158\/1078-0432.CCR-19-2169"},{"key":"32196","doi-asserted-by":"crossref","unstructured":"Garzon R, Savona M, Baz R. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. 2017; 129(24):3165-3174.","DOI":"10.1182\/blood-2016-11-750158"},{"key":"32197","doi-asserted-by":"crossref","unstructured":"Chari A, Vogl DT, Gavriatopoulou M. Oral selinexor-dexamethasone for tripleclass refractory multiple myeloma. N Engl J Med. 2019; 381(8):727-738.","DOI":"10.1056\/NEJMoa1903455"},{"key":"32198","doi-asserted-by":"crossref","unstructured":"Machlus KR, Wu SK, Vijey P. Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis. Blood. 2017; 130(9):1132-1143.","DOI":"10.1182\/blood-2016-11-752840"},{"key":"32199","doi-asserted-by":"crossref","unstructured":"Wang AY, Weiner H, Green M. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol. 2018; 11(1):4.","DOI":"10.1186\/s13045-017-0550-8"},{"key":"32200","unstructured":"Tay T, Somasundaram N, Khoo LP. Treatment outcomes of T and naturalkiller\/ T-cell lymphoma with ifosfamide, carboplatin, etoposide (ICE) chemotherapy. Br J Haematol. 2019; 185(Suppl. 1):3-202."},{"key":"32201","doi-asserted-by":"crossref","unstructured":"Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)- based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2003; 14(Suppl 1):i5-10.","DOI":"10.1093\/annonc\/mdg702"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2020.251454\/72576","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2020.251454\/73898","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10082\/72576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:58:30Z","timestamp":1794045510000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2020.251454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2020.251454","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,5]]}}}